Cat. No：GM-C30929
Product：H_EGFR(A763-Y764-ins-FQEA-C797S) BAF3 Cell Line
Cat. No：GM-C30929
Product：H_EGFR(A763-Y764-ins-FQEA-C797S) BAF3 Cell Line
Cell Growth Medium：RPMI 1640+10% FBS+1% P.S+0.25 μg/mL Puromycin
Cell Freezing Medium: 90% FBS+10% DMSO
Assay Buffer：RPMI 1640+10% FBS+1% P.S
EGFR is a member of the receptor tyrosine kinase (TK) family. It is widely distributed on the surface of mammalian fibroblasts, epithelial cells, and other cell types, and the EGFR signaling pathway plays an important role in physiological processes such as cell proliferation and differentiation. When mutations occur in EGFR, it leads to the persistent activation of the EGFR signaling pathway even in the absence of ligand binding, resulting in abnormal cell proliferation. EGFR mutations have been identified in various tumors, such as non-small cell lung cancer, breast cancer, colorectal cancer, and head and neck squamous cell carcinoma (HNSCC). There are several tyrosine kinase inhibitors (TKI) targeting EGFR mutations, including Afatinib, Erlotinib, Gefitinib, Osimertinib (AZD 9291), and Cetuximab.
BA/F3 cells are a type of IL-3-dependent precursor B cell, and certain protein kinases can replace IL-3 to support the growth of BA/F3 cells. By using inhibitors to antagonize this effect, this characteristic can be utilized for research on kinase inhibitors.
Cat. No：GM-C30929
Product：H_EGFR(A763-Y764-ins-FQEA-C797S) BAF3 Cell Line
Cell Growth Medium：RPMI 1640+10% FBS+1% P.S+0.25 μg/mL Puromycin
Cell Freezing Medium: 90% FBS+10% DMSO
Assay Buffer：RPMI 1640+10% FBS+1% P.S
EGFR is a member of the receptor tyrosine kinase (TK) family. It is widely distributed on the surface of mammalian fibroblasts, epithelial cells, and other cell types, and the EGFR signaling pathway plays an important role in physiological processes such as cell proliferation and differentiation. When mutations occur in EGFR, it leads to the persistent activation of the EGFR signaling pathway even in the absence of ligand binding, resulting in abnormal cell proliferation. EGFR mutations have been identified in various tumors, such as non-small cell lung cancer, breast cancer, colorectal cancer, and head and neck squamous cell carcinoma (HNSCC). There are several tyrosine kinase inhibitors (TKI) targeting EGFR mutations, including Afatinib, Erlotinib, Gefitinib, Osimertinib (AZD 9291), and Cetuximab.
BA/F3 cells are a type of IL-3-dependent precursor B cell, and certain protein kinases can replace IL-3 to support the growth of BA/F3 cells. By using inhibitors to antagonize this effect, this characteristic can be utilized for research on kinase inhibitors.
